Watson Pharmaceuticals could reap big benefits from the approval of its version of the blood pressure med Toprol XL, because two rival generic drugs were suspended because of manufacturing problems. "We get these opportunities every once in a while and this is one of those unique opportunities," Watson spokeswoman Patty Eisenhaur told Reuters, referring to the sudden recent disappearance from the U.S. market of the rival Novartis and KV Pharmaceutical generics. Report